Innovative glaucoma research award

Article

The Glaucoma Research Foundation (GRF) awarded the 2010 Shaffer Prize for Innovative Glaucoma Research to Kate Keller, PhD. Dr Keller is Research Assistant Professor, Department of Ophthalmology at Casey Eye Institute in Portland, Oregon.

The Glaucoma Research Foundation (GRF) awarded the 2010 Shaffer Prize for Innovative Glaucoma Research to Kate Keller, PhD. Dr Keller is Research Assistant Professor, Department of Ophthalmology at Casey Eye Institute in Portland, Oregon.

Kate Keller, PhD, was awarded the Shaffer Prize for her research investigating the role of Glycosaminoglycans (GAGs) in fluid outflow resistance in the trabecular meshwork of the eye. In primary open-angle glaucoma, there is increased resistance to aqueous flow through the trabecular meshwork, which results in increased intraocular pressure (IOP). GAGs are long sugar chains synthesized by the addition of sugar residues by specific enzymes, and are a likely source of outflow resistance. Experimental results from this study could potentially lead to new therapies for lowering eye pressure in patients with primary open-angle glaucoma.

Dr. Keller published her results in the scientific journals Investigative Ophthalmology and Visual Science and Experimental Eye Research. A native of Scotland, Dr. Keller received her PhD from the University of Edinburgh and obtained postdoctoral training as a Fellow in the laboratories of Dr Nick Morris and Dr Lynn Sakai.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.